Bernstein believes that concerns raised about the deal between Allergan (AGN) and Teva (TEVA) are unrealistic, and it does not see increased risk of Teva abandoning the deal. The firm says that Allergan is worth more to Teva now than at the time the deal was made, due to progress that Allergan has made on a number of generic drugs. Additionally, Bernstein believes that the deal will help Teva make a needed shift to more differentiated products, and it does not think that the FTC's lawsuit against Endo (ENDP) will affect the Teva deal. The firm thinks that Teva very much wants the Allergan deal to go through.

Vanda Pharmaceuticals "announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ(R) Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp." CEO Mihael H. Polymeropoulos stated: "We are disappointed that the Supreme Court has decided not to hear our case and clarify the lower court standard for obviousness in patent law. However, we are pleased that our case has drawn attention to an area of law that has broad and significant implications in life sciences innovation."